Investigation of Baseline Factors Associated with a Favorable Response to Initial MAO-B Inhibitor Treatment in Parkinson’s Disease
Objective: This study aims to identify pre-treatment indicators for Parkinson’s disease (PD) patients who respond well to monoamine oxidase type B inhibitors (MAOBIs). Background: MAOBIs,…Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges
Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study
Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Inpatient Multimodal Care Improves Parkinsonian Symptoms Regardless Of Race Or Ethnicity
Objective: To verify demographic characteristics of patients with Parkinson’s disease (PD) completing a two-week inpatient multimodal intensive neurorehabilitation and care (iMINC) program and whether iMINC…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…Establishing Clinical Education and Patient Support Programs for Continuous Subcutaneous Apomorphine Infusion (CSAI) in the United States
Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people…Do Peripheral Inflammatory Markers Predict Impulse Control Disorders in Parkinson’s Disease? Insights from a Retrospective Study
Objective: To evaluate the relationship between hematological inflammatory markers—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)—and ICD development in PD patients treated with…
- « Previous Page
- 1
- …
- 338
- 339
- 340
- 341
- 342
- …
- 1942
- Next Page »